Cargando…

Challenges in diagnosis and biomarker testing for RET-altered lung and thyroid cancer care: an international mixed-method study

BACKGROUND: The introduction of new targeted therapies for RET-altered lung and thyroid cancers (LC/TC) has impacted pathologists’ practice by making genomic testing more relevant. Variations in health systems and treatment access result in distinct clinical challenges and barriers. This study aimed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lazure, Patrice, Sireci, Anthony, Subbiah, Vivek, Murray, Suzanne, Grohé, Christian, Sherman, Steven I., Kelly, Elizabeth, Bubach, Patrick, Péloquin, Sophie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241144/ https://www.ncbi.nlm.nih.gov/pubmed/37277734 http://dx.doi.org/10.1186/s12909-023-04396-w

Ejemplares similares

Challenges in the care of patients with RET-altered thyroid cancer: a multicountry mixed-methods study
por: Murray, Suzanne, et al.
Publicado: (2023)

Precision therapy for RET-altered cancers with RET inhibitors
por: Thein, Kyaw Z., et al.
Publicado: (2021)

Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers
por: Adashek, Jacob J., et al.
Publicado: (2021)

RET kinase inhibitors for RET-altered thyroid cancers
por: Vodopivec, Danica M., et al.
Publicado: (2022)

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
por: Gouda, Mohamed A., et al.
Publicado: (2023)

Challenges associated with the integration of immuno-oncology agents in clinical practice
por: Lazure, Patrice, et al.
Publicado: (2022)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases
por: Andreev-Drakhlin, Alexander, et al.
Publicado: (2020)

Gaps and barriers in the implementation and functioning of antimicrobial stewardship programmes: results from an educational and behavioural mixed methods needs assessment in France, the United States, Mexico and India
por: Lazure, Patrice, et al.
Publicado: (2022)

Gaps and barriers in the implementation and functioning of antimicrobial stewardship programmes: results from an educational and behavioural mixed-methods needs assessment in France, the United States, Mexico and India—authors’ response
por: Lazure, Patrice, et al.
Publicado: (2023)

Selective RET kinase inhibition for patients with RET-altered cancers
por: Subbiah, V, et al.
Publicado: (2018)

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
por: Rosen, Ezra Y., et al.
Publicado: (2022)

SUN-LB75 The Anti-Tumor Activity of the Selective Ret Inhibitor Selpercatinib (LOXO-292) in Medullary Thyroid Cancer Is Independent of the Specific RET Mutation
por: Cabanillas, Maria E, et al.
Publicado: (2020)

Author Correction: The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
por: Rosen, Ezra Y., et al.
Publicado: (2022)

ret/PTC-1 expression alters the immunoprofile of thyroid follicular cells
por: Denning, Karen, et al.
Publicado: (2008)

Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours.
por: Santoro, M., et al.
Publicado: (1993)

Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma
por: Dias-Santagata, Dora, et al.
Publicado: (2020)

Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA
por: Della Corte, C.M., et al.
Publicado: (2021)

RET Copy Number Alteration in Medullary Thyroid Cancer Is a Rare Event Correlated with RET Somatic Mutations and High Allelic Frequency
por: Ramone, Teresa, et al.
Publicado: (2020)

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
por: Solomon, Benjamin J., et al.
Publicado: (2020)

Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States
por: Hess, Lisa M., et al.
Publicado: (2021)

On the RET Rearrangements in Chernobyl-Related Thyroid Cancer
por: Jargin, Sergei V.
Publicado: (2012)

Destabilizing RET in targeted treatment of thyroid cancers
por: Gild, M L, et al.
Publicado: (2015)

International challenges without borders: a descriptive study of family physicians' educational needs in the field of diabetes
por: Murray, Suzanne, et al.
Publicado: (2011)

Correction: Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States
por: Hess, Lisa M., et al.
Publicado: (2023)

Education needs of nurses in thrombosis and hemostasis: An international, mixed‐methods study
por: Lazure, Patrice, et al.
Publicado: (2018)

Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma
por: Werner, Rudolf A., et al.
Publicado: (2022)

Clinical practice gaps and challenges in non‐alcoholic steatohepatitis care: An international physician needs assessment
por: Lazure, Patrice, et al.
Publicado: (2022)

Chinese siblings with hereditary medullary thyroid carcinoma caused by RET mutation: implications for RET oncogene detection
por: Huang, Qin, et al.
Publicado: (2020)

Emergence and Targeting of Acquired and Hereditary Resistance to Multikinase RET Inhibition in Patients With RET-Altered Cancer
por: Wirth, Lori J., et al.
Publicado: (2019)

Allel RET+3 : T a medullary thyroid cancer
por: Pławski, A, et al.
Publicado: (2011)

RET Gene Fusions in Malignancies of the Thyroid and Other Tissues
por: Santoro, Massimo, et al.
Publicado: (2020)

Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET–rearranged thyroid cancer
por: Raman, Renuka, et al.
Publicado: (2022)

Alterations of RET, Oncogene in Human Adrenal Tumors
por: Lin, Shiu‐Ru, et al.
Publicado: (1998)

RET rearrangements are actionable alterations in breast cancer
por: Paratala, Bhavna S., et al.
Publicado: (2018)

RET kinase alterations in targeted cancer therapy
por: Liu, Xuan, et al.
Publicado: (2020)

Precious Gene: The Application of RET-Altered Inhibitors
por: Gou, Qitao, et al.
Publicado: (2022)

Current perspectives on the management of patients with advanced RET-driven thyroid cancer in Europe
por: Elisei, Rossella, et al.
Publicado: (2023)

RET-Altered Cancers—A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity
por: Desilets, Antoine, et al.
Publicado: (2023)

Clinical care in hepatocellular carcinoma: A mixed methods assessment of experiences and challenges of oncology professionals
por: Jacobs, Ginny, et al.
Publicado: (2022)

Selpercatinib Treatment of RET-Mutated Thyroid Cancers Is Associated With Gastrointestinal Adverse Effects
por: Tsang, Venessa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r594f7b6h3imi790abo4cmgdn3